Schonfeld Strategic Advisors’s Theravance Biopharma TBPH Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.85M	Buy	+108,879	New	+$1.8M	0.01%	1106
2026 Q1	–	Sell	-16,555	Closed	-$310K	–	2658
2025 Q4	$310K	Buy	+16,555	New	+$275K	﹤0.01%	1571
2023 Q4	–	Sell	-57,426	Closed	-$496K	–	2198
2023 Q3	$496K	Buy	57,426 +39,350	+218%	+$380K	﹤0.01%	1209
2023 Q2	$187K	Buy	+18,076	New	+$200K	﹤0.01%	1588
2023 Q1	–	Sell	-29,160	Closed	-$327K	–	2638
2022 Q4	$327K	Buy	+29,160	New	+$306K	﹤0.01%	1751

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Schonfeld Strategic Advisors's TBPH Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 108,879 shares worth $1.85M. The stake represents 0.01% of the portfolio and ranks #1106 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in TBPH as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in TBPH in Q4 2022 and has held it in 5 quarters since. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Schonfeld Strategic Advisors held 108,879 shares of Theravance Biopharma worth $1.85M as of Q2 2026.
Theravance Biopharma was a new Schonfeld Strategic Advisors position in Q2 2026.
Theravance Biopharma made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1106 holding.
Schonfeld Strategic Advisors first reported a position in Theravance Biopharma in Q4 2022 and has held it in 5 quarters since.
180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.